Applied Genetic Technologies (AGTC) Tops Q4 EPS by $0.12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021
September 23, 2021 4:05 PM EDT-Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability; multiple data readouts expected in 2021 and 2022-
-Pre-Clinical programs moving to IND enabling animal studies-
-Company adds experienced industry veterans to board and management team-
-Company to host management update and webcast today at 4:30pm ET-
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies... More
